Preventing tomorrow's sudden cardiac death today. Dissemination of effective therapies for sudden cardiac death prevention

Sana M. Al-Khatib, Gillian D. Sanders, Mark Carlson, Aida Cicic, Anne Curtis, Gregg C. Fonarow, Peter W. Groeneveld, David Hayes, Paul Heidenreich, Daniel Mark, Eric Peterson, Eric N. Prystowsky, Philip Sager, Marcel E. Salive, Kevin Thomas, Clyde W. Yancy, Wojciech Zareba, Douglas Zipes

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Because the burden of sudden cardiac death (SCD) is substantial, it is important to use all guideline-driven therapies to prevent SCD. Among those therapies is the implantable cardioverter defibrillator (ICD). When indicated, ICD use is beneficial and cost-effective. Unfortunately, studies suggest that most patients who have indications for this therapy for primary or secondary prevention of SCD are not receiving it. To explore potential reasons for this underuse and to propose potential facilitators for ICD dissemination, the Duke Center for the Prevention of SCD at the Duke Clinical Research Institute (Durham, NC) organized a think tank meeting of experts on this issue. The meeting took place on December 12 and 13, 2007, and it included representatives of clinical cardiology, cardiac electrophysiology, general internal medicine, economics, health policy, the US Food and Drug Administration, the Centers for Medicare and Medicaid Services, the Agency for Health care Research and Quality, and the device and pharmaceutical industry. Although the meeting was funded by industry participants, this article summarizing the presentations and discussions that occurred at the meeting presents the expert opinion of the authors.

Original languageEnglish
Pages (from-to)613-622
Number of pages10
JournalAmerican Heart Journal
Volume156
Issue number4
DOIs
StatePublished - Oct 2008

Fingerprint

Sudden Cardiac Death
Implantable Defibrillators
Cardiac Electrophysiology
Centers for Medicare and Medicaid Services (U.S.)
Health Services Research
Drug Industry
Expert Testimony
United States Food and Drug Administration
Primary Prevention
Therapeutics
Internal Medicine
Health Policy
Secondary Prevention
Cardiology
Industry
Economics
Guidelines
Costs and Cost Analysis
Equipment and Supplies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Al-Khatib, S. M., Sanders, G. D., Carlson, M., Cicic, A., Curtis, A., Fonarow, G. C., ... Zipes, D. (2008). Preventing tomorrow's sudden cardiac death today. Dissemination of effective therapies for sudden cardiac death prevention. American Heart Journal, 156(4), 613-622. https://doi.org/10.1016/j.ahj.2008.05.027

Preventing tomorrow's sudden cardiac death today. Dissemination of effective therapies for sudden cardiac death prevention. / Al-Khatib, Sana M.; Sanders, Gillian D.; Carlson, Mark; Cicic, Aida; Curtis, Anne; Fonarow, Gregg C.; Groeneveld, Peter W.; Hayes, David; Heidenreich, Paul; Mark, Daniel; Peterson, Eric; Prystowsky, Eric N.; Sager, Philip; Salive, Marcel E.; Thomas, Kevin; Yancy, Clyde W.; Zareba, Wojciech; Zipes, Douglas.

In: American Heart Journal, Vol. 156, No. 4, 10.2008, p. 613-622.

Research output: Contribution to journalArticle

Al-Khatib, SM, Sanders, GD, Carlson, M, Cicic, A, Curtis, A, Fonarow, GC, Groeneveld, PW, Hayes, D, Heidenreich, P, Mark, D, Peterson, E, Prystowsky, EN, Sager, P, Salive, ME, Thomas, K, Yancy, CW, Zareba, W & Zipes, D 2008, 'Preventing tomorrow's sudden cardiac death today. Dissemination of effective therapies for sudden cardiac death prevention', American Heart Journal, vol. 156, no. 4, pp. 613-622. https://doi.org/10.1016/j.ahj.2008.05.027
Al-Khatib, Sana M. ; Sanders, Gillian D. ; Carlson, Mark ; Cicic, Aida ; Curtis, Anne ; Fonarow, Gregg C. ; Groeneveld, Peter W. ; Hayes, David ; Heidenreich, Paul ; Mark, Daniel ; Peterson, Eric ; Prystowsky, Eric N. ; Sager, Philip ; Salive, Marcel E. ; Thomas, Kevin ; Yancy, Clyde W. ; Zareba, Wojciech ; Zipes, Douglas. / Preventing tomorrow's sudden cardiac death today. Dissemination of effective therapies for sudden cardiac death prevention. In: American Heart Journal. 2008 ; Vol. 156, No. 4. pp. 613-622.
@article{ab1becd9964e4663b93ea617381a814d,
title = "Preventing tomorrow's sudden cardiac death today. Dissemination of effective therapies for sudden cardiac death prevention",
abstract = "Because the burden of sudden cardiac death (SCD) is substantial, it is important to use all guideline-driven therapies to prevent SCD. Among those therapies is the implantable cardioverter defibrillator (ICD). When indicated, ICD use is beneficial and cost-effective. Unfortunately, studies suggest that most patients who have indications for this therapy for primary or secondary prevention of SCD are not receiving it. To explore potential reasons for this underuse and to propose potential facilitators for ICD dissemination, the Duke Center for the Prevention of SCD at the Duke Clinical Research Institute (Durham, NC) organized a think tank meeting of experts on this issue. The meeting took place on December 12 and 13, 2007, and it included representatives of clinical cardiology, cardiac electrophysiology, general internal medicine, economics, health policy, the US Food and Drug Administration, the Centers for Medicare and Medicaid Services, the Agency for Health care Research and Quality, and the device and pharmaceutical industry. Although the meeting was funded by industry participants, this article summarizing the presentations and discussions that occurred at the meeting presents the expert opinion of the authors.",
author = "Al-Khatib, {Sana M.} and Sanders, {Gillian D.} and Mark Carlson and Aida Cicic and Anne Curtis and Fonarow, {Gregg C.} and Groeneveld, {Peter W.} and David Hayes and Paul Heidenreich and Daniel Mark and Eric Peterson and Prystowsky, {Eric N.} and Philip Sager and Salive, {Marcel E.} and Kevin Thomas and Yancy, {Clyde W.} and Wojciech Zareba and Douglas Zipes",
year = "2008",
month = "10",
doi = "10.1016/j.ahj.2008.05.027",
language = "English",
volume = "156",
pages = "613--622",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Preventing tomorrow's sudden cardiac death today. Dissemination of effective therapies for sudden cardiac death prevention

AU - Al-Khatib, Sana M.

AU - Sanders, Gillian D.

AU - Carlson, Mark

AU - Cicic, Aida

AU - Curtis, Anne

AU - Fonarow, Gregg C.

AU - Groeneveld, Peter W.

AU - Hayes, David

AU - Heidenreich, Paul

AU - Mark, Daniel

AU - Peterson, Eric

AU - Prystowsky, Eric N.

AU - Sager, Philip

AU - Salive, Marcel E.

AU - Thomas, Kevin

AU - Yancy, Clyde W.

AU - Zareba, Wojciech

AU - Zipes, Douglas

PY - 2008/10

Y1 - 2008/10

N2 - Because the burden of sudden cardiac death (SCD) is substantial, it is important to use all guideline-driven therapies to prevent SCD. Among those therapies is the implantable cardioverter defibrillator (ICD). When indicated, ICD use is beneficial and cost-effective. Unfortunately, studies suggest that most patients who have indications for this therapy for primary or secondary prevention of SCD are not receiving it. To explore potential reasons for this underuse and to propose potential facilitators for ICD dissemination, the Duke Center for the Prevention of SCD at the Duke Clinical Research Institute (Durham, NC) organized a think tank meeting of experts on this issue. The meeting took place on December 12 and 13, 2007, and it included representatives of clinical cardiology, cardiac electrophysiology, general internal medicine, economics, health policy, the US Food and Drug Administration, the Centers for Medicare and Medicaid Services, the Agency for Health care Research and Quality, and the device and pharmaceutical industry. Although the meeting was funded by industry participants, this article summarizing the presentations and discussions that occurred at the meeting presents the expert opinion of the authors.

AB - Because the burden of sudden cardiac death (SCD) is substantial, it is important to use all guideline-driven therapies to prevent SCD. Among those therapies is the implantable cardioverter defibrillator (ICD). When indicated, ICD use is beneficial and cost-effective. Unfortunately, studies suggest that most patients who have indications for this therapy for primary or secondary prevention of SCD are not receiving it. To explore potential reasons for this underuse and to propose potential facilitators for ICD dissemination, the Duke Center for the Prevention of SCD at the Duke Clinical Research Institute (Durham, NC) organized a think tank meeting of experts on this issue. The meeting took place on December 12 and 13, 2007, and it included representatives of clinical cardiology, cardiac electrophysiology, general internal medicine, economics, health policy, the US Food and Drug Administration, the Centers for Medicare and Medicaid Services, the Agency for Health care Research and Quality, and the device and pharmaceutical industry. Although the meeting was funded by industry participants, this article summarizing the presentations and discussions that occurred at the meeting presents the expert opinion of the authors.

UR - http://www.scopus.com/inward/record.url?scp=54849176600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54849176600&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2008.05.027

DO - 10.1016/j.ahj.2008.05.027

M3 - Article

C2 - 18926144

AN - SCOPUS:54849176600

VL - 156

SP - 613

EP - 622

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4

ER -